London - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Phenylephrine HCl Injection, USP, in 500mcg/5mL and 1,000mcg/10mL doses.

The product has been launched in the US in ready-to-use vials. It is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Hikma will be marketing this product under the name IMMPHENTIV and is introducing the first FDA approved 1,000mcg/10mL presentation to the US market, broadening the choice of medicines available to hospitals.

Hikma is a top three supplier of generic injectable medicines by volume in the US[1], with a growing portfolio of more than 150 products. We are continuously expanding our portfolio of essential medicines and introducing new dosage forms that enhance patient care.

This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States.

Contact:

Tel: +44 (0) 20 7399 2760

Fax: +44 (0) 20 7399 2761

(C) 2023 Electronic News Publishing, source ENP Newswire